Inclusion Criteria:

1. Participants who have a positive SARS-CoV-2 test result ;

2. Participants who have been diagnosed with mild or ordinary type of COVID-19
infection;

3. Participants whose serum hyaluronic acid level was higher than the upper limit of
normal value;

4. Participants who must agree to adhere to contraception restrictions;

5. Participants who understand and agree to comply with planned study procedures;

6. Participants who give signed consent which includes compliance with the requirements
and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion Criteria:

1. Participants who have any of the following conditions when screening:

1. ALT or AST > 5 ULN;

2. Scr > 1.5 ULN or Ccr < 50 mL/min;

3. TBIL > 2ULN ;

4. HGB ≤ 90 g/ L;

5. PLT ≤ 75×10^9/ L;

2. Participants who have suspected/active infections during the screening period
including uncontrolled active bacterial, viral or fungal infections that require
systemic treatment, except COVID-19 virus infections;

3. Participants who have any active autoimmune diseases during the screening period and
need to be treated with immunosuppressants, including biological agents;

4. Participants who have a medical history of organ transplantation, or plan for organ
transplantation including liver transplantation;

5. Participants who need a loading dose of anti-platelet drugs, such as aspirin (>300
mg/day) and clopidogrel (>300 mg/day);

6. Participants who have a medical history of central nervous system and digestive
system bleeding, or a tendency of gastrointestinal bleeding, local active ulcer
lesions included, in the last three months;

7. Participants who have biliary obstruction;

8. Female participants who are pregnant or breast-feeding or plan to be pregnant within
this study period;

9. Male participants whose wife or partner plan to be pregnant within this study
period.

10. Participants who have taken the drugs containing coumarin compounds, such as
warfarin, within 3 days before screening;

11. Participants who have other diseases requiring hospitalization and/or in a need of
surgical treatment within 7 days before screening, or have suffered from
life-threatening diseases within 30 days before screening;

12. Participants who have known allergies to any of the components used in the
formulation of the interventions;

13. Participants who have taken a part in a clinical study of an investigational
intervention in the last 28 days. After 5 half-lives or 28 days, whichever is
longer, can be allowed for screening;

14. Participants who are not suitable for this trial, and with any medical condition
will compromise their own safety.